4D Molecular Therapeutics (FDMT) Receivables - Other (2021 - 2022)
4D Molecular Therapeutics' (FDMT) quarterly Receivables - Other came in at $700000.0 in Q4 2022, little changed year-on-year from $700000.0 in Q4 2021, and little changed on a QoQ basis from $700000.0 in Q4 2021.
4D Molecular Therapeutics (FDMT) Receivables - Other (2021 - 2022) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 2 years of Receivables - Other data on file, last reported at $700000.0 in Q4 2022.
- On a quarterly basis, Receivables - Other changed 0.0% year-over-year to $700000.0 in Q4 2022; TTM through Dec 2022 was $700000.0, a 0.0% change from a year earlier, with the FY2022 full-year figure at $700000.0, changed 0.0% from the prior year.
- Receivables - Other for Q4 2022 stood at $700000.0, roughly flat from $700000.0 in the prior quarter.
- Over the last five years, Receivables - Other for FDMT reached as high as $700000.0 in Q4 2021 and fell as low as $561000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 700,000.00 |
| Dec 31, 2022 | 700,000.00 |
| Dec 31, 2021 | 700,000.00 |
| Dec 31, 2021 | 700,000.00 |
| Mar 31, 2021 | 561,000.00 |
| Mar 31, 2021 | 561,000.00 |